Scarica l'app Stockscreener
5.325
13.41%
-0.825
Dopo l'orario di chiusura:
5.13
-0.195
-3.66%
Precedente Chiudi:
$6.15
Aprire:
$6.22
Volume 24 ore:
1.34M
Relative Volume:
1.94
Capitalizzazione di mercato:
$368.04M
Reddito:
-
Utile/perdita netta:
$-93.56M
Rapporto P/E:
-1.8776
EPS:
-2.8361
Flusso di cassa netto:
$-85.76M
1 W Prestazione:
-6.33%
1M Prestazione:
-17.31%
6M Prestazione:
+259.80%
1 anno Prestazione:
+136.67%
Intervallo 1D:
$5.32
$6.305
Intervallo di 1 settimana:
$5.32
$6.70
Portata 52W:
$0.8801
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Nome
Pepgen Inc
Settore
Industria
Telefono
703-456-8000
Indirizzo
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
5.325 | 368.04M | 0 | -93.56M | -85.76M | -2.8361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-09 | Iniziato | Guggenheim | Buy |
| 2024-12-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-21 | Iniziato | H.C. Wainwright | Buy |
Pepgen Inc Borsa (PEPG) Ultime notizie
FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial - Sahm
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Aug Volume: Is PepGen Inc stock a smart retirement pickPrice Action & Technical Pattern Recognition Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen CEO McArthur sells $32875 in shares By Investing.com - Investing.com Nigeria
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com Nigeria
How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN
PepGen unveils new research at MDA2026 poster session - Traders Union
Research Analysts Offer Predictions for PepGen Q1 Earnings - MarketBeat
Profit Review: Can PepGen Inc. stock double in the next year2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Momentum: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEARTrade Entry Summary & Short-Term Trading Alerts - baoquankhu1.vn
PepGen CEO McArthur sells $32875 in shares - Investing.com
Surprises Report: How does PepGen Inc correlate with NasdaqJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
PepGen (PEPG) CFO’s 2,084-share automatic sale covers RSU tax withholding - Stock Titan
PepGen (PEPG) CEO share sale covers RSU tax withholding obligations - Stock Titan
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - wjfw.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
PepGen Still On Track For PGN-EDODM1 Readouts Despite FDA Partial Hold - Citeline News & Insights
PepGen: Stock Slides On FDA Study HoldI'm Firmly On The Sidelines (NASDAQ:PEPG) - Seeking Alpha
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - BioPharma Dive
Stifel reiterates Buy on PepGen stock amid partial clinical hold By Investing.com - Investing.com India
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com Nigeria
PepGen: Clinical and Safety Uncertainties, FDA Partial Hold, and Valuation Gap Support Underperform Rating - TipRanks
Grocery Outlet Posts Downbeat Q4 Earnings, Joins SES AI, PepGen And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
PepGen stock slides on FDA partial hold (PEPG:NASDAQ) - Seeking Alpha
PepGen Updates EDO Platform and DM1 Program Outlook - TipRanks
PepGen falls 20% despite earnings beat on FDA hold concerns - Investing.com India
Why Is PepGen Stock Falling Thursday?PepGen (NASDAQ:PEPG) - Benzinga
FDA places partial clinical hold on PepGen’s DM1 trial By Investing.com - Investing.com Canada
US FDA puts partial clinical hold on PepGen’s muscle disease drug trial - 1470 & 100.3 WMBD
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - PharmiWeb.com
PepGen Announces Regulatory Updates on FREEDOM2 - pharmiweb.com
Stocks to Watch : Broadcom, StubHub, PepGen, Veeva Systems - marketscreener.com
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com South Africa
PepGen reports Q4 EPS (27c), consensus (39c) - TipRanks
PepGen announce FDA placed partial clinical hold on Phase 2 trial of PGN-EDODM1 - TipRanks
PepGen's Phase 2 Trial of Drug to Treat Multisystem Disorder Placed on Hold by US FDA - marketscreener.com
PepGen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
US FDA puts partial clinical hold on PepGen's muscle disease drug trial - AOL.com
Biotech firm PepGen's Q4 net loss narrows - TradingView
PepGen Faces FDA Partial Hold Amid Ongoing FREEDOM2 Trial - TipRanks
PepGen stock plunges 26% on FDA partial clinical hold By Investing.com - Investing.com Canada
PepGen (NASDAQ:PEPG) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
PepGen IncU.S. FDA places Freedom2 trial on partial clinical hold related to preclinical pharmacology and toxicology - marketscreener.com
Pepgen IncU.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology - TradingView
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pepgen Inc Azioni (PEPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):